ArticleScientific reports2025
Mapping the BCSC-1 interactome in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BCSC-1 (breast cancer suppressor candidate-1), the official gene symbol VWA5A (von Willebrand factor A domain containing 5 A), is downregulated in a variety of cancer types including breast cancer. The role of BCSC-1 in tumorigenesis and the underlying mechanisms are poorly understood. One of the ways to predict a spectrum of functions of an unknown protein is to identify the protein-protein interaction network involving it. Flag-pLV-Neo-BCSC1 or the empty vector were stably transfected into breast cancer cells MCF-7. The levels of BCSC1 expression were identified by Western blotting. Co-immunoprecipitation assay coupled with liquid chromatography with tandem mass spectrometry (Co-IP-MS) and bioinformatic analysis were done to study protein-protein interactions. A subset of interacting proteins was validated by immunofluorescence (IF). IF was also conducted to determine the cell migration of BCSC-1. The pEGFP-C3 plasmids with full-length and truncated BCSC-1 were transiently transfected into breast cancer cells to identify domains of BCSC-1 guiding the subcellular location. 341 interacting partners of BCSC-1 were significantly enriched in Flag-BCSC-1 against negative control. These interactors included the lysosome and the proteasome related to proteostatic pathways, the peroxisome involved in lipid metabolism, endocytosis components in the vesicle transport pathway, and the regulation of actin cytoskeleton. STAT1, STAT3, and CDC42, identified among the interacting partners, co-localized with BCSC-1. In addition, BCSC-1 distributed to the leading edge of migrating breast cancer cells. VIT (vault protein inter-α-trypsin) domain of BCSC-1 is required in the regulation of cell migration. BCSC-1 might exert diverse functions through protein-protein interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.